Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HENRIK BO ILLUM

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1982805164
CMS profile
818448
Location
BEDFORD, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$466.63

22 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $466.63 22

By paying entity

PY2024 · entire year · sorted by reported total

Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HENRIK BO ILLUM

NPI 1982805164 · CMS profile ID 818448

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

BEDFORD, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1982805164?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HENRIK BO ILLUM, NPI 1982805164, CMS profile ID 818448. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1982805164?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). HENRIK BO ILLUM, NPI 1982805164, CMS profile ID 818448. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1982805164?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
HENRIK BO ILLUM, NPI 1982805164, CMS profile ID 818448, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1982805164?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

22 matching records · $466.63 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 22 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–22 of 22.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ARRAY BIOPHARMA INC $23.0310/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132134567 CMS
Celgene Corporation $15.3010/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101093774 CMS
Daiichi Sankyo Inc. $29.6010/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089436146 CMS
Novartis Pharmaceuticals Corporation $16.4009/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086785883 CMS
Medtronic, Inc. $29.4209/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119579213 CMS
E.R. Squibb & Sons, L.L.C. $23.3809/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101264625 CMS
EMD Serono, Inc. $30.9408/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120243561 CMS
Celgene Corporation $20.8108/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101093762 CMS
Celgene Corporation $22.3707/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101093760 CMS
GlaxoSmithKline, LLC. $17.5707/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116471264 CMS
Janssen Biotech, Inc. $25.2706/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078693941 CMS
Tempus AI, Inc $26.7006/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150166630 CMS
Celgene Corporation $23.3206/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101093754 CMS
Celgene Corporation $23.8005/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101093752 CMS
Celgene Corporation $11.0405/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101093750 CMS
SOBI, INC $24.4904/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141419478 CMS
PFIZER INC. $20.8503/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131300152 CMS
Celgene Corporation $23.8002/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101093742 CMS
Novartis Pharmaceuticals Corporation $13.2402/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086785881 CMS
Agios Pharmaceuticals, Inc. $14.9502/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149645548 CMS
Kite Pharma, Inc. $14.5901/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1128613455 CMS
Novartis Pharmaceuticals Corporation $15.7601/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086785879 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $218.19 5
PY2021 $11.92 1
PY2022 $388.68 8
PY2023 $308.84 15
PY2024 $466.63 22
PY2025 $915.63 26

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $30,785.70 23
PY2024 Principal investigator $56,382.74 49
PY2023 Principal investigator $148,965.97 74
PY2022 Principal investigator $217,097.35 91
PY2021 Principal investigator $222,524.42 113
PY2020 Principal investigator $248,821.20 67
PY2019 Recipient $1,250.00 1
PY2019 Principal investigator $428,314.17 79

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

80 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Amgen Inc. $6,678.00 12/24/2019 Non-covered Recipient Entity
US ONC RESEARCH LLC
Prospective Observational Study of Onpro vs SOC No dispute reported 06/30/2026 675778773
Principal investigator 1 Eisai Inc. $175.00 12/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702510067
Principal investigator 1 Seattle Genetics, Inc. $1,206.00 12/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678822169
Principal investigator 1 Eisai Inc. $1,481.00 11/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702510069
Principal investigator 1 Eisai Inc. $1,481.00 11/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702510071
Principal investigator 1 Seattle Genetics, Inc. $2,620.00 11/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678822157
Principal investigator 1 Seattle Genetics, Inc. $1,281.00 11/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678822159
Principal investigator 1 Seattle Genetics, Inc. $275.00 11/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678822167
Principal investigator 1 Seattle Genetics, Inc. $1,281.00 11/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678822177
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,060.00 11/05/2019 Non-covered Recipient Entity
Us Oncology Res Llc
A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC Nivolumab as Maintenance after Induction Chemotherapy or as First Line Treatment, Alone or in Combination of Standard of Care Therapies No dispute reported 06/30/2026 639761533
Principal investigator 1 EMD Serono, Inc. $750.00 10/15/2019 Non-covered Recipient Entity
Texas Oncology, Pa
MS200647-0037 No dispute reported 06/30/2026 703033145
Principal investigator 1 Eisai Inc. $1,481.00 10/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702510063
Principal investigator 1 Eisai Inc. $1,088.00 10/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702510065
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 10/15/2019 Non-covered Recipient Entity
Ghs Greenville Memorial Hospital
PCYC-1134M-CA No dispute reported 06/30/2026 673102385
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 10/15/2019 Non-covered Recipient Entity
Texas Oncology, P.A.
PCYC-1134M-CA No dispute reported 06/30/2026 673102547
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $638.00 10/15/2019 Non-covered Recipient Entity
Ghs Greenville Memorial Hospital
PCYC-1134M-CA No dispute reported 06/30/2026 673102643
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 10/15/2019 Non-covered Recipient Entity
Texas Oncology, P.A.
PCYC-1134M-CA No dispute reported 06/30/2026 673102659
Principal investigator 1 Eisai Inc. $1,481.00 09/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702510055
Principal investigator 1 Eisai Inc. $1,481.00 09/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702510057
Principal investigator 1 Eisai Inc. $1,481.00 09/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702510061
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $120.00 08/15/2019 Non-covered Recipient Entity
Us Oncology Res Llc
A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC Nivolumab as Maintenance after Induction Chemotherapy or as First Line Treatment, Alone or in Combination of Standard of Care Therapies No dispute reported 06/30/2026 639761529
Principal investigator 1 Eisai Inc. $175.00 08/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702510059
Principal investigator 1 Seattle Genetics, Inc. $275.00 08/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678822151
Principal investigator 1 Eisai Inc. $1,358.00 07/17/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702510035
Principal investigator 1 Eisai Inc. $1,481.00 07/17/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702510037
Principal investigator 1 Eisai Inc. $1,358.00 07/17/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702510039
Principal investigator 1 Eisai Inc. $1,481.00 07/17/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702510041
Principal investigator 1 Eisai Inc. $1,481.00 07/17/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702510043
Principal investigator 1 Eisai Inc. $175.00 07/17/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702510045
Principal investigator 1 Eisai Inc. $1,481.00 07/17/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702510047
Principal investigator 1 Eisai Inc. $1,020.00 07/17/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702510051
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $638.00 07/15/2019 Non-covered Recipient Entity
Texas Oncology Southwest Fort Worth Pet
PCYC-1134M-CA No dispute reported 06/30/2026 673101653
Principal investigator 1 Seattle Genetics, Inc. $182.00 07/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678822129
Principal investigator 1 Seattle Genetics, Inc. $275.00 07/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678822145
Principal investigator 1 Seattle Genetics, Inc. $182.00 07/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678822147
Principal investigator 1 Seattle Genetics, Inc. $182.00 07/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678822149
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,250.00 07/12/2019 Non-covered Recipient Entity
Us Oncology Res Llc
A Phase IIIbIV Safety Trial of Nivolumab BMS-936558 in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen No dispute reported 06/30/2026 639761527
Principal investigator 1 Eisai Inc. $1,088.00 06/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702510049
Principal investigator 1 EMD Serono, Inc. $7,650.00 05/15/2019 Non-covered Recipient Entity
Texas Oncology, Pa
MS 200647-0037 No dispute reported 06/30/2026 703036221
Principal investigator 1 Eisai Inc. $175.00 05/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702510053
Principal investigator 1 Seattle Genetics, Inc. $1,020.00 05/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678822075
Principal investigator 1 Seattle Genetics, Inc. $2,720.00 05/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678822077
Principal investigator 1 Seattle Genetics, Inc. $847.00 05/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678822079
Principal investigator 1 Seattle Genetics, Inc. $1,020.00 05/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678822107
Principal investigator 1 Seattle Genetics, Inc. $1,020.00 05/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678822109
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,468.00 05/01/2019 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC Nivolumab as Maintenance after Induction Chemotherapy or as First Line Treatment, Alone or in Combination of Standard of Care Therapies No dispute reported 06/30/2026 639761531
Principal investigator 1 Acerta Pharma LLC $3,750.00 04/23/2019 Non-covered Recipient Entity
Us Oncology Research
A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 685002775
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $638.00 04/15/2019 Non-covered Recipient Entity
Texas Oncology Southwest Fort Worth Pet
PCYC-1134M-CA No dispute reported 06/30/2026 673099165
Principal investigator 1 Seattle Genetics, Inc. $175.00 04/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678822057
Principal investigator 1 Seattle Genetics, Inc. $2,435.00 04/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678822059
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $64,802.00 03/15/2019 Non-covered Recipient Entity
Texas Oncology
Phase IIIII 1L CRC NivoCT wpt segmentationrational combos No dispute reported 06/30/2026 639761543
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 03/15/2019 Non-covered Recipient Entity
Texas Oncology, P.A.
PCYC-1134M-CA No dispute reported 06/30/2026 673093709
Principal investigator 1 Seattle Genetics, Inc. $2,161.00 03/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678822051
Principal investigator 1 Seattle Genetics, Inc. $2,161.00 03/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678822097
Principal investigator 1 Amgen Inc. $72,578.00 02/26/2019 Non-covered Recipient Entity
US ONC RESEARCH LLC
Prospective Observational Study of Onpro vs SOC No dispute reported 06/30/2026 675795886
Principal investigator 1 Amgen Inc. $48,715.00 02/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
Prospective Observational Study of Onpro vs SOC No dispute reported 06/30/2026 675793817
Principal investigator 1 Celgene Corporation $3,570.00 02/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
Celgene - Connect MM No dispute reported 06/30/2026 675419105
Principal investigator 1 Seattle Genetics, Inc. $2,161.00 02/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678822047
Principal investigator 1 Seattle Genetics, Inc. $275.00 02/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678822049
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $19,531.00 02/01/2019 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC Nivolumab as Maintenance after Induction Chemotherapy or as First Line Treatment, Alone or in Combination of Standard of Care Therapies No dispute reported 06/30/2026 639761535
Recipient Acerta Pharma LLC $1,250.00 01/25/2019 Covered Recipient Physician A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 685006165
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,550.00 01/15/2019 Non-covered Recipient Entity
Texas Oncology
Phase IIIb IV Safety Trial of Nivolumab BMS-936558 in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 639754817
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,146.00 01/15/2019 Non-covered Recipient Entity
Texas Oncology
SUSTAIN, event driven trial No dispute reported 06/30/2026 639761537
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,868.00 01/15/2019 Non-covered Recipient Entity
Texas Oncology
Adaptive Pan Malignancy Study for indications in which there is no approved immunomodulating therapy or BMS registration pathway No dispute reported 06/30/2026 639761539
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $9,163.00 01/15/2019 Non-covered Recipient Entity
Texas Oncology
Phase III 1L Gastric combo vs nivo CT No dispute reported 06/30/2026 639761541
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $9,426.00 01/15/2019 Non-covered Recipient Entity
Texas Oncology
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in US Community Oncology Practices No dispute reported 06/30/2026 639761545
Principal investigator 1 Eisai Inc. $300.00 01/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702510031
Principal investigator 1 Eisai Inc. $1,481.00 01/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702510033
Principal investigator 1 Eisai Inc. $1,358.00 01/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors No dispute reported 06/30/2026 702510073
Principal investigator 1 Novartis Pharmaceuticals Corporation $516.00 01/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY PA SOUTHWEST FT WORTH
A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF LEE011 IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE HER2 NEGATIVE ADVANCED BREAST CANCER WHO RECEIVED NO PRIOR HORMONAL THERAPY FOR ADVANCED DI No dispute reported 06/30/2026 640727873
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $638.00 01/15/2019 Non-covered Recipient Entity
Texas Oncology, P.A.
PCYC-1134M-CA No dispute reported 06/30/2026 673093413
Principal investigator 1 Seattle Genetics, Inc. $1,020.00 01/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678822039
Principal investigator 1 Seattle Genetics, Inc. $2,435.00 01/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678822041
Principal investigator 1 Seattle Genetics, Inc. $2,720.00 01/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678822043
Principal investigator 1 Seattle Genetics, Inc. $1,020.00 01/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678822091
Principal investigator 1 Seattle Genetics, Inc. $1,020.00 01/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678822093
Principal investigator 1 Seattle Genetics, Inc. $1,020.00 01/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above No dispute reported 06/30/2026 678822095
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $12,569.00 01/09/2019 Non-covered Recipient Entity
Us Oncology Res Llc
Phase III 1L Gastric nivo ipi vs nivo CT vs CT No dispute reported 06/30/2026 639761549
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $85,330.65 01/04/2019 Non-covered Recipient Entity
Us Oncology Res Llc
Phase II III 1L CRC Nivo CT w pt segmentation rational combos No dispute reported 06/30/2026 708963945
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,961.52 01/01/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY BEDFORD
TWO ARM RANDOMIZED PHASE 3 STUDY IN HIGH RISK NSCLC COMPARING CANAKINUMAB VS PLACEBO IN ADJUVANT SETTING No dispute reported 06/30/2026 640727807